Myeloma Center

You are here

Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.

TitleStem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.
Publication TypeJournal Article
Year of Publication2008
AuthorsMark T, Stern J, Furst JR, Jayabalan D, Zafar F, Larow A, Pearse RN, Harpel J, Shore T, Schuster MW, Leonard JP, Christos PJ, Coleman M, Niesvizky R
JournalBiol Blood Marrow Transplant
Volume14
Issue7
Pagination795-8
Date Published2008 Jul
ISSN1523-6536
KeywordsAged, Antigens, CD34, Antineoplastic Combined Chemotherapy Protocols, Clarithromycin, Cyclophosphamide, Dexamethasone, Drug Therapy, Combination, Female, Granulocyte Colony-Stimulating Factor, Hematinics, Hematopoietic Stem Cell Mobilization, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Multiple Myeloma, Remission Induction, Stem Cells, Thalidomide, Transplantation, Autologous, Treatment Outcome
Abstract

A total of 28 treatment-naïve patients with stage II or III multiple myeloma (MM) were treated with the combination of clarithromycin, lenalidomide, and dexamethasone (BiRD). Stem cells were collected following granulocyte-colony stimulating factor (G-CSF) or cyclophosphamide (Cy) plus G-CSF mobilization at maximum response. Sufficient stem cells for 2 autologous stem cell transplants were collected from all patients mobilized with Cy plus G-CSF, versus 33% mobilized with G-CSF alone (P < .0001). The duration of prior lenalidomide therapy did not correlate with success of stem cell harvests (P = .91). In conclusion, Cy can be added to G-CSF for stem cell mobilization to successfully overcome the suppressive effect of prior treatment with lenalidomide.

DOI10.1016/j.bbmt.2008.04.008
Alternate JournalBiol. Blood Marrow Transplant.
PubMed ID18541199
PubMed Central IDPMC3626097
Grant ListK23 CA109260 / CA / NCI NIH HHS / United States
UL1 RR024996 / RR / NCRR NIH HHS / United States
K23 CA109260-01 / CA / NCI NIH HHS / United States